A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.

MLA

Rosenthal, Allison, et al. “A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy.” American Journal of Hematology, vol. 92, no. 5, May 2017, pp. 467–72. EBSCOhost, https://doi.org/10.1002/ajh.24693.

APA

Rosenthal, A., Dueck, A. C., Ansell, S., Gano, K., Conley, C., Nowakowski, G. S., Camoriano, J., Leis, J. F., Mikhael, J. R., Keith Stewart, A., Inwards, D., Dingli, D., Kumar, S., Noel, P., Gertz, M., Porrata, L., Russell, S., Colgan, J., Fonseca, R., & Habermann, T. M. (2017). A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. American Journal of Hematology, 92(5), 467–472. https://doi.org/10.1002/ajh.24693

Chicago

Rosenthal, Allison, Amylou C. Dueck, Stephen Ansell, Katherine Gano, Christopher Conley, Grzegorz S. Nowakowski, John Camoriano, et al. 2017. “A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy.” American Journal of Hematology 92 (5): 467–72. doi:10.1002/ajh.24693.